3-Year Clinical Follow-Up of the RIBS IV Clinical Trial: A Prospective Randomized Study of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis in Coronary Arteries Previously Treated With Drug-Eluting Stents
| Autor: | Alfonso, Fernando, Pérez-Vizcayno, María José, Cuesta, Javier, García Del Blanco, Bruno, García-Touchard, Arturo, López-Mínguez, José Ramón, Masotti, Mónica, Zueco, Javier, Cequier, Angel, Velázquez, Maite, Moreno, Raúl, Mainar, Vicente, Domínguez, Antonio, Moris, Cesar, Molina, Eduardo, Rivero, Fernando, Jiménez-Quevedo, Pilar, Gonzalo, Nieves, Fernández-Pérez, Cristina, RIBS IV Study Investigators (Under the Auspices of the Interventional Cardiology Working Group of the Spanish Society of Cardiology) |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Male
Time Factors Cardiovascular Agents Drug-Eluting Stents drug-eluting ballon(s) Coronary Artery Disease Middle Aged drug-eluting stent(s) in-stent restenosis Cardiac Catheters Coronary Restenosis Percutaneous Coronary Intervention Treatment Outcome Coated Materials Biocompatible Risk Factors Spain everolimus-eluting stent(s) Retreatment Humans Female Everolimus Prospective Studies Angioplasty Balloon Coronary Aged |
| Popis: | This study sought to compare the long-term safety and efficacy of drug-eluting balloons (DEB) and everolimus-eluting stents (EES) in patients with in-stent restenosis (ISR) of drug-eluting stents (DES). Treatment of patients with DES-ISR remains a challenge. The RIBS IV (Restenosis Intra-Stent of Drug-Eluting Stents: Drug-Eluting Balloons vs Everolimus-Eluting Stents) trial is a prospective multicenter randomized clinical trial comparing DEB and EES in patients with DES-ISR. The pre-specified comparison of the 3-year clinical outcomes obtained with these interventions is the main objective of the present study. A total of 309 patients with DES-ISR were randomized to DEB (n = 154) or EES (n = 155). At angiographic follow-up, the in-segment minimal lumen diameter was larger in the EES arm (2.03 ± 0.7 mm vs. 1.80 ± 0.6 mm; p 1 year) target lesion revascularization (2.6% vs. 4%) and target vessel revascularization (4% vs. 6.6%) was similar in the 2 arms. Rates of cardiac death (3.9% vs. 3.2%), myocardial infarction (2.6% vs. 4.5%), and stent thrombosis (1.3% vs. 2.6%) at 3 years were also similar in both arms. The 3-year clinical follow-up of this randomized clinical trial demonstrates that in patients with DES-ISR, EES reduce the need for repeat interventions compared with DEB. (Restenosis Intra-Stent of Drug-Eluting Stents: Drug-Eluting Balloons vs Everolimus-Eluting Stents [RIBS IV]; NCT01239940). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|